AU652939B2 - Targeted protection from cytotoxins - Google Patents

Targeted protection from cytotoxins

Info

Publication number
AU652939B2
AU652939B2 AU79026/91A AU7902691A AU652939B2 AU 652939 B2 AU652939 B2 AU 652939B2 AU 79026/91 A AU79026/91 A AU 79026/91A AU 7902691 A AU7902691 A AU 7902691A AU 652939 B2 AU652939 B2 AU 652939B2
Authority
AU
Australia
Prior art keywords
antagonist
conjugate
cytotoxin
tumor
binding agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU79026/91A
Other languages
English (en)
Other versions
AU7902691A (en
Inventor
Catherine H Wu
George Y Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CONNECTICUT THE, University of
Original Assignee
University of Connecticut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Connecticut filed Critical University of Connecticut
Publication of AU7902691A publication Critical patent/AU7902691A/en
Application granted granted Critical
Publication of AU652939B2 publication Critical patent/AU652939B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/67—Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6895—Rescue therapy; Agonist-antagonist; Antidotes; Targeted rescue or protection, e.g. by folic acid-folinic acid or conjugated to antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
AU79026/91A 1990-05-11 1991-05-10 Targeted protection from cytotoxins Ceased AU652939B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52265390A 1990-05-11 1990-05-11
US522653 1990-05-11
PCT/US1991/003291 WO1991017761A1 (en) 1990-05-11 1991-05-10 Targeted protection from cytotoxins

Publications (2)

Publication Number Publication Date
AU7902691A AU7902691A (en) 1991-12-10
AU652939B2 true AU652939B2 (en) 1994-09-15

Family

ID=24081756

Family Applications (1)

Application Number Title Priority Date Filing Date
AU79026/91A Ceased AU652939B2 (en) 1990-05-11 1991-05-10 Targeted protection from cytotoxins

Country Status (5)

Country Link
EP (1) EP0538268A4 (ja)
JP (1) JPH05508398A (ja)
AU (1) AU652939B2 (ja)
CA (1) CA2082507A1 (ja)
WO (1) WO1991017761A1 (ja)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5490991A (en) * 1986-07-03 1996-02-13 Advanced Magnetics, Inc. Directed delivery of radioprotectants using a receptor specific carrier
DK0594803T3 (da) * 1992-03-23 2004-03-08 Kenneth Naoyuki Matsumura Sammensætning til reduktion af bivirkninger af et lægemiddel
US5449720A (en) * 1993-05-24 1995-09-12 Biotech Australia Pty Limited Amplification of the VB12 uptake system using polymers
WO1995018636A2 (en) * 1994-01-11 1995-07-13 Targetech Inc Hepatocyte-targeted drug conjugates
US5830686A (en) * 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
US6057299A (en) * 1994-01-13 2000-05-02 Calydon, Inc. Tissue-specific enhancer active in prostate
ATE376062T1 (de) 1997-08-04 2007-11-15 Cell Genesys Inc Enhancer des menschlichen glandulären kallikreingens, vektoren die ihn enthalten und methoden für seine verwendung
GB0916749D0 (en) 2009-09-23 2009-11-04 Mologic Ltd Peptide cleaning agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2579497B2 (ja) * 1987-09-07 1997-02-05 オリエンタル酵母工業株式会社 肝臓疾患診断剤
AU8628291A (en) * 1990-09-25 1992-04-15 University Of Connecticut, The Prolonging expression of polynucleotides introduced into a cell

Also Published As

Publication number Publication date
AU7902691A (en) 1991-12-10
EP0538268A4 (en) 1993-05-12
EP0538268A1 (en) 1993-04-28
CA2082507A1 (en) 1991-11-12
WO1991017761A1 (en) 1991-11-28
JPH05508398A (ja) 1993-11-25

Similar Documents

Publication Publication Date Title
US5087616A (en) Cytotoxic drug conjugates and their delivery to tumor cells
Masquelier et al. Low-density lipoprotein as a carrier of antitumoral drugs: in vivo fate of drug-human low-density lipoprotein complexes in mice
AU628053B2 (en) Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US9221867B2 (en) Method for transporting a compound across the blood-brain barrier
EP1859041B1 (en) Aprotinin polypeptides for transporting a compound across the blood-brain barrier
CA2445826C (en) Treatment and diagnosis of macrophage mediated disease
Fiume et al. Drug targeting in antiviral chemotherapy: A chemically stable conjugate of 9-β-d-arabinofuranosyl-adenine 5'-monophosphate with lactosaminated albumin accomplishes a selective delivery of the drug to liver cells
US20030119724A1 (en) Ligands to enhance cellular uptake of biomolecules
AU760211C (en) Hemoglobin-haptoglobin complexes
AU652939B2 (en) Targeted protection from cytotoxins
Seymour Soluble polymers for lectin-mediated drug targeting
Fiume et al. Galactosylated poly (L-lysine) as a hepatotropic carrier of 9-β-D-arabinofuranosyladenine 5'-monophosphate
Fujita et al. Control of in vivo fate of albumin derivatives utilizing combined chemical modification
US6638508B2 (en) Modified avidin-type molecules as targeting agents for the liver and cells of the reticuloendothelial system
EP1937310B1 (en) Use of conjugates of doxorubicin with lactosaminated albumin
EP1279405A1 (en) Drugs retained in target tissue over long time
RO120711B1 (ro) Reactivi de legare a receptorului de calcitonină şi variante marcate ale acestora
Fiume et al. Inhibition of woodchuck hepatitis virus replication by adenine arabinoside monophosphate coupled to lactosaminated poly-L-lysine and administered by intramuscular route
Schechter et al. Organ selective delivery using a tissue-directed sreptavidin-biotin system: targeting 5-fluorouridine via TNP-streptavidin
Lim et al. The enhancement of liver targetability of [3H] methotrexate-galactosylated serum albumin conjugate in mice
EP1351700B1 (en) Conjugates of nucleosides with lactosaminated human albumine
CA2326720C (en) Hemoglobin-haptoglobin complexes
STEINMANN et al. A novel methotrexate-albumin (MTX-RSA)-conjugate causes significant growth delay of O-342 ovarian-carcinoma in-vivo